Celgene Announces Results of Two Studies Evaluating Combo of Revlimid ... Benzinga Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from two studies evaluating the combination of REVLIMID^® (lenalidomide) and rituximab in various non-Hodgkin's lymphomas ... Two Studies Evaluating the Combination of REVLIMID ® and rituximab in Non ... |
